Anixa Biosciences Inc (ANIX) Actualités

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th...

Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire SAN...

Form 4 - Statement of changes in beneficial ownership of securities

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy

Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy PR...

Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology

Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology PR Newswire SAN JOSE, Calif...

Anixa Biosciences Announces $5 Million Share Repurchase Program

Anixa Biosciences Announces $5 Million Share Repurchase Program PR Newswire SAN JOSE, Calif., July 15, 2024...

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial PR Newswire SAN JOSE...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities